氟西汀治疗KCNT1变异所致婴儿期迁移性局灶性癫痫:一项开放标签研究
本研究纳入3例携带KCNT1新发变异、临床表型为婴儿期迁移性局灶性癫痫(EIMFS)的患儿,体外电生理证实3种变异均呈功能获得性效应,10μM氟西汀可阻断野生型与突变型KCNT1通道;氟西汀治疗使癫痫发作频率减少25-75%,视觉注意力、参与度和肌张力改善。作者认为氟西汀可能是KCNT1功能获得性变异所致EIMFS的潜在靶向药物,需进一步研究评估长期疗效与安全性。
要点
- 3例KCNT1功能获得性变异EIMFS患儿接受氟西汀治疗,发作频率减少25-75%
- 体外10μM氟西汀可阻断野生型与突变型KCNT1通道电流
- 除1例短暂性运动障碍外未报告不良事件,作者认为氟西汀可能是潜在靶向药物
核心结论
- 氟西汀可能是KCNT1功能获得性变异所致EIMFS的潜在靶向药物,需进一步研究评估其长期疗效与安全性。
研究设计与样本
- 开放标签研究,纳入3例携带与EIMFS相关的新发KCNT1遗传变异的儿科患者。
- 在哺乳动物中国仓鼠卵巢细胞异源表达通道上,用膜片钳电生理进行功能与药理学研究,评估氟西汀在体外对抗变异所致功能效应的能力。
- 基线及研究期间每3个月评估神经心理评估、脑电图和癫痫日记,并监测心电图与药物血药浓度以评估安全性。
主要发现
- 所有3种KCNT1变异在体外均显示功能获得性效应,10μM氟西汀阻断野生型和突变型KCNT1通道,从而对抗变异所致功能效应。
- 氟西汀治疗使癫痫发作频率出现不同程度的减少(25-75%)。
- 报告视觉注意力、参与度和肌张力改善。
- 除1例患者出现短暂性运动障碍外未报告不良事件,该运动障碍可能与氟西汀血浆水平升高有关。
关键数值与推荐
- 体外实验使用氟西汀10μM,阻断野生型和突变型KCNT1通道。
- 氟西汀治疗使癫痫发作频率减少25-75%。
- 研究期间每3个月评估神经心理评估、脑电图和癫痫日记。
- 1例患者出现短暂性运动障碍,可能与氟西汀血浆水平升高有关。
局限性
- 原文结论提出需进一步研究评估氟西汀的长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gain-of-function (GoF) variants in KCNT1 encoding for potassium channels are associated with different epilepsy phenotypes, including epilepsy of infancy with migrating focal seizures (EIMFS), other early infantile developmental and epileptic encephalopathies, and focal epilepsy. Fluoxetine blocks currents from both wild-type (WT) and mutant KCNT1 channels with GoF in vitro features. In this study, we tested the hypothesis that treatment with fluoxetine might improve clinical outcome in patients with EIMFS carrying GoF variants in KCNT1 channels showing in vitro sensitivity to fluoxetine blockade. METHODS: We enrolled three pediatric patients carring de novo KCNT1 genetic variants linked to EIMFS. Functional and pharmacological studies to assess fluoxetine's ability to counteract in vitro variant-induced functional effects were performed with patch-clamp electrophysiology on heterologous channel expression in mammalian Chinese hamster ovary cells. Neuropsychological assessment, electroencephalogram and seizure diary were evaluated at baseline and every 3 months during the study. Electrocardiography and blood levels of medications were monitored for safety. RESULTS: All 3 KCNT1 variants displayed GoF effects in vitro. Exposure to fluoxetine (10μM) blocked both WT and mutant KCNT1 channels, therefore, counteracting variant-induced functional effects. Treatment with fluoxetine caused a variable reduction of seizure frequency (25-75%). Improvement in visual attention, participation, and muscle tone was also reported. No adverse events were reported except for transient dyskinesia in 1 patient, which was probably related to an increase in fluoxetine plasma level. INTERPRETATION: Fluoxetine may be a potential targeted medication in EIMFS caused by KCNT1 GoF variants. Further research is needed to assess its long-term efficacy and safety. ANN NEUROL 2025;98:48-61.
引用
- Trivisano M, Mosca I, Salimbene L, et al. Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study. Ann Neurol. 2025. PMID: 39981956. doi:10.1002/ana.27213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。